12:00 AM
 | 
Sep 01, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GVAX vaccine for prostate cancer: Phase III discontinued

Cell Genesys stopped the Phase III VITAL-2 trial of GVAX immunotherapy based on a recommendation by the study’s IDMC, which observed 67 deaths in the GVAX arm vs. 47 in the control arm. The international, open-label VITAL-2 trial was evaluating GVAX immunotherapy plus Taxotere docetaxel versus Taxotere plus prednisone in...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >